CNS Pharmaceuticals, Inc.
CNSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $22,919 | $237,172,500 | $162,756,360 | $891,977,760 |
| - Cash | $6,461 | $549 | $10,055 | $5,005 |
| + Debt | $326 | $301 | $410 | $388 |
| Enterprise Value | $16,784 | $237,172,252 | $162,746,715 | $891,973,143 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$3 | -$4 | -$12 | -$13 |
| % Margin | – | – | – | – |
| EBITDA | -$14,838 | -$18,861 | -$15,255 | -$14,473 |
| % Margin | – | – | – | – |
| Net Income | -$14,858 | -$18,851 | -$15,274 | -$14,495 |
| % Margin | – | – | – | – |
| EPS Diluted | -38.87 | -60 | -134.64 | -6.36 |
| % Growth | 35.2% | 55.4% | -2,017% | – |
| Operating Cash Flow | -$17,113 | -$14,140 | -$10,558 | -$13,538 |
| Capital Expenditures | -$4 | -$4 | -$4 | -$6 |
| Free Cash Flow | -$17,117 | -$14,144 | -$10,562 | -$13,544 |